Supercharge Your Innovation With Domain-Expert AI Agents!

Application for Aphanamgrandiol A in preparation of medicines for treating chronic obstructive pulmonary disease

A technology for chronic obstructive pulmonary diseases, applied in drug combinations, respiratory diseases, pharmaceutical formulations, etc., can solve problems such as difficult to obtain satisfactory curative effect, different pathogenesis, slow progress in drug treatment research, etc., to achieve outstanding substantive features, strong inhibitory effect

Inactive Publication Date: 2015-05-20
HUAIAN UNIV SCI PARK MANAGEMENT CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no drug that can curb the progressive development of COPD, and the research progress of its drug treatment is quite slow. At present, the drug for treating asthma is often used in clinical practice to treat COPD. Because the pathogenesis of COPD is different from that of asthma, it is difficult to obtain satisfactory curative effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application for Aphanamgrandiol A in preparation of medicines for treating chronic obstructive pulmonary disease
  • Application for Aphanamgrandiol A in preparation of medicines for treating chronic obstructive pulmonary disease
  • Application for Aphanamgrandiol A in preparation of medicines for treating chronic obstructive pulmonary disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Embodiment 1: the preparation of the compound Aphanamgrandiol A tablet involved in the present invention:

[0013] Take 5 grams of compound Aphanamgrandiol A, add 195 grams of dextrin, mix well, and make 1000 tablets by conventional compression.

Embodiment 2

[0014] Embodiment 2: the preparation of compound Aphanamgrandiol A capsules involved in the present invention:

[0015] Get 5 grams of compound Aphanamgrandiol A, add 195 grams of starch, mix well, pack into capsules and make 1000 capsules.

[0016] The following pharmacodynamic experiments will further illustrate its drug activity.

[0017] Methods: SPF grade female BALB / c mice, 18-20g, were randomly divided into normal control group, model control group, positive control group (terbutaline, 10mg / kg, intragastric administration), drug treatment group (Aphanamgrandiol A 5, 10, 20mg / kg, intragastric administration), 10 rats in each group. Put the mice in a 4L container, smoke daily (Jinjian brand cigarettes, tar content less than 16mg), five times a week, for four consecutive weeks, and administer the drug by intragastric administration 1 hour before daily smoking. One hour after fumigation, anesthetize with sodium phenobarbital, perfuse the lungs with 0.6 mL of pre-cooled PB...

experiment example 1

[0018] Experimental example 1: Aphanamgrandiol A inhibits the production of inflammatory mediators in bronchoalveolar lavage fluid (BALF) of COPD mice

[0019] (1) Inhibitory effect of Aphanamgrandiol A on TNFα production in BALF of COPD mice

[0020] The proinflammatory cytokine TNFα is an initiating factor in the pathogenesis of COPD. The level of TNFα in COPD patients is higher than that of normal people, and the cultured bronchial epithelial cells can secrete TNFα in contact with cigarette smoke. TNFα can promote neutrophil degranulation, induce mucosal cell proliferation and hypersecretion, increase the production of IL-8 in epithelial cells, increase the production of matrix metalloproteinases in macrophages, and promote airway hyperresponsiveness. The purpose of this experiment is to investigate the effect of Aphanamgrandiol A on the production of TNFα in the BALF of COPD mice. The results are shown in Table 1.

[0021] Table 1 Effect of Aphanamgrandiol A on TNFα prod...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel application for Aphanamgrandiol A in preparation of medicines for treating chronic obstructive pulmonary disease. The application for Aphanamgrandiol A in preparation of medicines for treating chronic obstructive pulmonary disease is disclosed for the first time; Aphanamgrandiol A has a new framework type, and an unexpectedly high inhibitory activity for chronic obstructive pulmonary disease, so that the possibility of giving any revelation by other compounds is avoided; and Aphanamgrandiol A has prominent substantive features, and an obviously remarkable improvement in case of being used for resisting chronic obstructive pulmonary disease.

Description

technical field [0001] The present invention relates to a new application of compound Aphanamgrandiol A, in particular to the application of Aphanamgrandiol A in the preparation of medicines for treating chronic obstructive pulmonary disease. Background technique [0002] Chronic obstructive pulmonary disease (chronic obstructive pulmonary disease, COPD) is a common chronic disease worldwide, currently ranked fourth in the global cause of death, according to the World Health Organization forecast, by 2020, COPD will be in the global disease incidence Ranked fifth and third among causes of death. [0003] COPD is a disease characterized by not fully reversible airflow limitation associated with an abnormal inflammatory response of the lungs to noxious gases or noxious particles, with chronic inflammation throughout the airways, lung parenchyma, and pulmonary vessels. The cells involved in COPD include inflammatory cells such as neutrophils, T lymphocytes, and macrophages. Wh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/366A61P11/00
Inventor 段现英
Owner HUAIAN UNIV SCI PARK MANAGEMENT CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More